Nicotinamide riboside (NR) is a naturally occurring compound that the body converts to NAD+, a molecule central to cellular energy production and stress response. Animal studies suggest NR might support healthy aging and metabolic health, but most human research has used oral supplements. This paper reports the first systematic safety data on injectable NR, addressing whether bypassing the digestive system might improve efficacy or tolerability. The researchers conducted two pilot Phase 1 trials: Trial 1 tested 45 people across nine different arms (three doses—placebo, NR, or NAD+—given via three routes: intramuscular, intravenous, or subcutaneous injections). Trial 2 involved 39 people self-administering 50 or 100 mg of NR via intramuscular or subcutaneous injection for three days. All participants completed the studies with 100% retention. Safety monitoring included vital signs, blood work, and adverse event reporting.
The key finding is reassuring: neither trial produced unexpected serious side effects. Blood pressure actually showed modest reductions in some groups, and standard blood chemistry remained stable. However, local discomfort was common—46% of Trial 2 participants reported pain beyond two minutes post-injection, and 43% experienced muscle soreness. Trial 2's subcutaneous NR arms showed within-group reductions in hsCRP (an inflammation marker), but the researchers correctly note this is hypothesis-generating only, given small sample size and baseline imbalances. No consistent metabolic or inflammatory patterns emerged across groups.
This is a credible first-step safety report, but with important limitations. These are tiny Phase 1 pilots (n=39–45 per trial) designed only to rule out gross harm, not to prove efficacy. The samples are not representative of the general population and lack detail on participant demographics. The preprint status means no peer review yet. The modest blood pressure reductions and hsCRP changes are intriguing but could easily be noise—larger, properly controlled studies are needed. The injectable route is novel and practically relevant (some people can't tolerate oral supplements), but we don't yet know whether injected NR outperforms oral NR or produces meaningful longevity benefits.
For the longevity research field, this paper fills a specific gap: establishing that injectable NR doesn't cause acute harm. This clears the path for Phase 2 efficacy trials if pursued. However, the field still lacks robust clinical evidence that NR itself (oral or injected) extends human lifespan or healthspan. The findings are preliminary and localized to safety; no claims about aging benefits can be made from this data. Larger, longer-duration trials with standard care controls and pre-registered endpoints will be needed to determine whether injectable NR offers real advantages for aging-related outcomes.
0 Comments
Log in to join the discussion.